Levels of Serum IL-6, TNF-αand C-reactive Protein in Elderly Patients with Moderate to Severe COPD at Stable Stage and Its Relationship with Lung Function_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

LiYi ,  ChenQizhang , ChenXiaojun , MaHui , WangJiaqi , ZhangXiaojun , WeiLing

Department of Respiratory Medicine, Cadre Ward, Gansu Provincial Hospital, Lanzhou, Gansu, 730000, China;

Corresponding?author：

ChenQizhang, Email: mj7690@163.com

Keywords：

Elderly patients; Chronic obstructive pulmonary disease; Stable phase; Interleukin-6; Tumor necrosis factor-α; C-reactive protein

DOI：

10.7507/1671-6205.2014111

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the relationship of levels of serum interleukin-6 (IL-6), tumor necrosis factor-α(TNF-α) and C-reactive protein (CRP) with lung function in elderly patients with stable COPD and whose pulmonary function classification was levelⅡor above. Methods Sixty elderly patients with stable COPD and with the pulmonary function classification of levelⅡor above and 35 age-matched healthy subjects in the Gansu Provincial Hospital from November 2012 to March in 2014 were recruited in the study.Serum IL-6, TNF-αand CRP levels were detected by electro-chemiluminescence immunoassay (ECLI), enzyme-linked immunosorbent assay and immunoturbidimetric assay, respectively.And their relationships with lung function were explored by Spearman correlation analysis. Results The levels of serum IL-6[(33.0±15.1) mg/L vs.(15.9±8.7) mg/L], TNF-α[(53.8±20.1) pg/mL vs.(22.2±8.0) pg/mL] and CRP[(8.7±3.9) mg/L vs.(5.8±2.3) mg/L] were significantly higher in the stable COPD patients than those in the healthy controls (P < 0.01).With the increase of COPD severity grade, the levels of serum IL-6, TNF-αand CRP increased gradually, and the lung function of FEV₁%pred and FEV₁/FVC decreased gradually (P < 0.05).The levels of serum IL-6, TNF-αand CRP were negatively correlated with lung function (P < 0.05). Conclusions There is airway inflammation in elderly patients with stable COPD.Airway inflammation may be the reason of the decline of pulmonary function in patients with stable COPD.

Citation： LiYi, ChenQizhang, ChenXiaojun, MaHui, WangJiaqi, ZhangXiaojun, WeiLing. Levels of Serum IL-6, TNF-αand C-reactive Protein in Elderly Patients with Moderate to Severe COPD at Stable Stage and Its Relationship with Lung Function. Chinese Journal of Respiratory and Critical Care Medicine, 2014, 13(5): 449-452. doi: 10.7507/1671-6205.2014111 Copy

1.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組.慢性阻塞性肺疾病診治指南(2013年修訂版).中華結核和呼吸雜志, 2013, 36:255-264.
2.	Young J, Donahue M, Farquhar M, Simpson C, G.R.Using opioids to treat dyspnea in advanced COPD:attitudes and experiences of family physicians and respiratory therapists.Can Fam Physician, 2012, 58:e401-407.
3.	何智輝, 陳平.慢性阻塞性肺疾病患者體內白介素-6和C反應蛋白質量濃度的變化及意義.中國實用內科雜志(臨床版), 2006, 26:989-991.
4.	Vestbo J, Hurd SS, R.R-R.The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)——why and what? Clin Respir J, 2012, 6:208-214.
5.	Rabe KF, Hurd S, Anzueto A, et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary.Am J Respir Crit Care Med, 2007, 17:532-555.
6.	Weissenbach J, Chernajovsky Y, Zeevi M, et al.Two interferon mRNAs in human fibroblasts:in vitro translation and Escherichia coli cloning studies.Proc Natl Acad Sci U S A, 1980, 77:7152-7156.
7.	吳紀珍, 馬利軍, 李素云, 等.慢性阻塞性肺疾病發作期與緩解期體內膠原、細胞因子變化及臨床意義.中國實用內科雜志(臨床版), 2005, 25:703-704.
8.	Lee TM, Lin MS, Chang NC.Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin.Am J Cardiol, 2008, 101:530-535.
9.	鵬銀芳, 于瑩, 陸志芳.IL-13和TNF-α在肺炎支原體肺炎兒童血清中的表達及意義.中國當代兒科雜志, 2010, 12:275-277.
10.	王海龍, 孫麗蓉.IL-6基因多態性與COPD肺動脈高壓研究進展.臨床肺科雜志, 2011, 16:1928-1930.
11.	王化強, 呂沈源.慢性阻塞性肺疾病患者血清IL-6與FEV₁相關性研究.中國醫藥科學, 2011, 01:114-115.
12.	王春雷, 蔡日丹, 康健, 等.慢性阻塞性肺病患者細胞因子與氧自由基的相關性.中國老年學雜志, 2010, 30:310-312.
13.	Quint JK, Wedzicha JA.The neutrophil in chronic obstructive pulmonary disease.J Allergy Clin Immunol, 2007, 119:1065-1071.
14.	de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al.C-reactive protein levels and clinically important predictive outcomes in stable COPD patients.Eur Respir J, 2006, 27:902-907.
15.	趙琳, 崔妙玲, 何志義.慢性阻塞性肺疾病合并癥的研究進展.醫學綜述, 2013, 19:3899-3901.
16.	Semik-Orzech A, Barczyk A, Pierzchala W.The role of interleukin 17 cytokine family in inducing allergic inflammation in the pulmonary tract.Pneumonol Alergol Pol, 2006, 74:409-413.
17.	Joppa P, Petrasova D, Stancak B, R.T.Systemic inflammation in patients with COPD and pulmonary hypertension.Chest, 2006, 130:326-333.
18.	Attaran D, Lari SM, Towhidi M, et al.Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis, 2010, 5:335-340.
19.	Moermans C, Heinen V, Nguyen M, et al.Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease.Cytokine, 2011, 56:298-304.
20.	苗麗君, 鄭富霞, 王靜, 等.炎性生物標志物與慢性阻塞性肺疾病患者生存關系的前瞻性研究.中華老年醫學雜志, 2013, 32:404-407.

1. 中華醫學會呼吸病學分會慢性阻塞性肺疾病學組.慢性阻塞性肺疾病診治指南(2013年修訂版).中華結核和呼吸雜志, 2013, 36:255-264.
2. Young J, Donahue M, Farquhar M, Simpson C, G.R.Using opioids to treat dyspnea in advanced COPD:attitudes and experiences of family physicians and respiratory therapists.Can Fam Physician, 2012, 58:e401-407.
3. 何智輝, 陳平.慢性阻塞性肺疾病患者體內白介素-6和C反應蛋白質量濃度的變化及意義.中國實用內科雜志(臨床版), 2006, 26:989-991.
4. Vestbo J, Hurd SS, R.R-R.The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)——why and what? Clin Respir J, 2012, 6:208-214.
5. Rabe KF, Hurd S, Anzueto A, et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary.Am J Respir Crit Care Med, 2007, 17:532-555.
6. Weissenbach J, Chernajovsky Y, Zeevi M, et al.Two interferon mRNAs in human fibroblasts:in vitro translation and Escherichia coli cloning studies.Proc Natl Acad Sci U S A, 1980, 77:7152-7156.
7. 吳紀珍, 馬利軍, 李素云, 等.慢性阻塞性肺疾病發作期與緩解期體內膠原、細胞因子變化及臨床意義.中國實用內科雜志(臨床版), 2005, 25:703-704.
8. Lee TM, Lin MS, Chang NC.Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin.Am J Cardiol, 2008, 101:530-535.
9. 鵬銀芳, 于瑩, 陸志芳.IL-13和TNF-α在肺炎支原體肺炎兒童血清中的表達及意義.中國當代兒科雜志, 2010, 12:275-277.
10. 王海龍, 孫麗蓉.IL-6基因多態性與COPD肺動脈高壓研究進展.臨床肺科雜志, 2011, 16:1928-1930.
11. 王化強, 呂沈源.慢性阻塞性肺疾病患者血清IL-6與FEV₁相關性研究.中國醫藥科學, 2011, 01:114-115.
12. 王春雷, 蔡日丹, 康健, 等.慢性阻塞性肺病患者細胞因子與氧自由基的相關性.中國老年學雜志, 2010, 30:310-312.
13. Quint JK, Wedzicha JA.The neutrophil in chronic obstructive pulmonary disease.J Allergy Clin Immunol, 2007, 119:1065-1071.
14. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al.C-reactive protein levels and clinically important predictive outcomes in stable COPD patients.Eur Respir J, 2006, 27:902-907.
15. 趙琳, 崔妙玲, 何志義.慢性阻塞性肺疾病合并癥的研究進展.醫學綜述, 2013, 19:3899-3901.
16. Semik-Orzech A, Barczyk A, Pierzchala W.The role of interleukin 17 cytokine family in inducing allergic inflammation in the pulmonary tract.Pneumonol Alergol Pol, 2006, 74:409-413.
17. Joppa P, Petrasova D, Stancak B, R.T.Systemic inflammation in patients with COPD and pulmonary hypertension.Chest, 2006, 130:326-333.
18. Attaran D, Lari SM, Towhidi M, et al.Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis, 2010, 5:335-340.
19. Moermans C, Heinen V, Nguyen M, et al.Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease.Cytokine, 2011, 56:298-304.
20. 苗麗君, 鄭富霞, 王靜, 等.炎性生物標志物與慢性阻塞性肺疾病患者生存關系的前瞻性研究.中華老年醫學雜志, 2013, 32:404-407.

Chinese Journal of Respiratory and Critical Care Medicine

Levels of Serum IL-6, TNF-αand C-reactive Protein in Elderly Patients with Moderate to Severe COPD at Stable Stage and Its Relationship with Lung Function

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content